Structured content output: clinical application and production information of tamsulosin

First paragraph: content overview
Tamsulosin is a selective α1-adrenergic receptor antagonist mainly used to treat urinary disorders caused by benign prostatic hyperplasia (BPH). This article will start from four dimensions: drug mechanism, clinical application, precautions and manufacturers, focusing on its role in relieving lower urinary tract symptoms, and secondly introducing drug safety and common preparations on the market.

Paragraph 2: Pharmacological mechanism and indications
Tamsulosin improves dysuria by specifically blocking α1 receptors in the prostate and bladder neck, relaxing smooth muscles. Clinical studies have shown (Quote 1) that it can improve symptoms such as frequent urination, urgency, and increased nocturia in BPH patients by more than 70%. Compared with ordinary α-blockers, its cardiovascular side effects are lower, but attention should be paid to the possible orthostatic hypotension that may occur when taking the drug for the first time.

Paragraph 3: Medication Precautions
According to the "Chinese Guidelines for the Diagnosis and Treatment of Urological Diseases" (Quote 2), a starting dose of 0.2 mg/d is recommended, and elderly patients need to monitor blood pressure. Contraindications include severe liver dysfunction and allergies to the drug. Common adverse reactions are dizziness (the incidence rate is about 3%) and nasal congestion, which mostly appear in the early stages of medication and resolve over time.

Paragraph 4: Market preparation information
The major domestic manufacturers and products are shown in the table below:

Paragraph 5: Summary
As a first-line drug for BPH, tamsulosin has both efficacy and safety advantages, but the dose needs to be adjusted individually. Patients should use it under the guidance of a doctor to avoid exacerbating the risk of hypotension when combined with antihypertensive drugs. With the development of sustained-release preparation technology, its clinical applicability will be further expanded.

Quote sources:
1. American Urological Association (AUA) "BPH Diagnosis and Treatment Guidelines" (2018 Edition)
2. Chinese Medical Association's "Guidelines for the Diagnosis and Treatment of Urological Diseases in China" (2022 Edition)
3. National Medical Products Administration Drug Database (NMPA)